[HTML][HTML] Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and …
CL Vale, S Burdett, LHM Rydzewska, L Albiges… - The lancet …, 2016 - thelancet.com
Background Results from large randomised controlled trials combining docetaxel or
bisphosphonates with standard of care in hormone-sensitive prostate cancer have emerged …
bisphosphonates with standard of care in hormone-sensitive prostate cancer have emerged …
[HTML][HTML] Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and …
J Beyer, P Albers, R Altena, J Aparicio, C Bokemeyer… - Annals of oncology, 2013 - Elsevier
Abstract In November 2011, the Third European Consensus Conference on Diagnosis and
Treatment of Germ-Cell Cancer (GCC) was held in Berlin, Germany. This third conference …
Treatment of Germ-Cell Cancer (GCC) was held in Berlin, Germany. This third conference …
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer
JJ Meeks, J Bellmunt, BH Bochner, NW Clarke… - European urology, 2012 - Elsevier
CONTEXT: Muscle-invasive bladder cancer (MIBC) is a disease with a pattern of
predominantly distant and early recurrences. Neoadjuvant cisplatin-based combination …
predominantly distant and early recurrences. Neoadjuvant cisplatin-based combination …
[HTML][HTML] Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive …
Background Long-term hormone therapy has been the standard of care for advanced
prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a …
prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a …
[HTML][HTML] Abiraterone for prostate cancer not previously treated with hormone therapy
ND James, JS de Bono, MR Spears… - … England Journal of …, 2017 - Mass Medical Soc
Background Abiraterone acetate plus prednisolone improves survival in men with relapsed
prostate cancer. We assessed the effect of this combination in men starting long-term …
prostate cancer. We assessed the effect of this combination in men starting long-term …
[HTML][HTML] Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial
CC Parker, ND James, CD Brawley, NW Clarke… - The Lancet, 2018 - thelancet.com
Background Based on previous findings, we hypothesised that radiotherapy to the prostate
would improve overall survival in men with metastatic prostate cancer, and that the benefit …
would improve overall survival in men with metastatic prostate cancer, and that the benefit …
Abiraterone and olaparib for metastatic castration-resistant prostate cancer
NW Clarke, AJ Armstrong, A Thiery-Vuillemin… - NEJM …, 2022 - evidence.nejm.org
Background Preclinical studies and results of a phase 2 trial of abiraterone and olaparib
suggest a combined antitumor effect when the poly (adenosine diphosphate [ADP]-ribose) …
suggest a combined antitumor effect when the poly (adenosine diphosphate [ADP]-ribose) …
[HTML][HTML] Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08 …
ND James, MR Spears, NW Clarke, DP Dearnaley… - European urology, 2015 - Elsevier
Abstract Background Prostate cancer (PCa) is the second most common disease among
men worldwide. It is important to know survival outcomes and prognostic factors for this …
men worldwide. It is important to know survival outcomes and prognostic factors for this …
[HTML][HTML] Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial
CC Parker, NW Clarke, AD Cook, HG Kynaston… - The Lancet, 2020 - thelancet.com
Background The optimal timing of radiotherapy after radical prostatectomy for prostate
cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy …
cancer is uncertain. We aimed to compare the efficacy and safety of adjuvant radiotherapy …
[HTML][HTML] Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the …
NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos… - Annals of …, 2019 - Elsevier
Background STAMPEDE has previously reported that the use of upfront docetaxel improved
overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long …
overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long …